Who is sponsoring NCT02362984?

NCT02362984 is sponsored by Dexa Medica Group.

What condition does NCT02362984 study?

NCT02362984 studies Acute Ischemic Stroke.

What drugs are being tested in NCT02362984?

Interventions: Placebo, DLBS1033.

What is the status of NCT02362984?

NCT02362984 is currently TERMINATED.

Last reviewed 2017-05-02 · How we verify

The Role of DLBS1033 in the Management of Acute Ischemic Stroke Patients: A Randomized Controlled Study

NCT02362984 Phase 3 TERMINATED

This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients.

Details

Lead sponsor	Dexa Medica Group
Phase	Phase 3
Status	TERMINATED
Enrolment	9
Start date	2014-10
Completion	2017-04

Conditions

Acute Ischemic Stroke

Interventions

Placebo
DLBS1033

Primary outcomes

Improvement in mNIHSS score — 7 days after treatment initiation
Change in functional outcomes as measured by The Modified National Institute of Health Stroke Scale (mNIHSS) from its baseline value

Countries

Indonesia